Zhejiang Hisun Pharmaceutical Co., Ltd. (600267.SS) Bundle
On November 17, 2025, a closer look at Zhejiang Hisun Pharmaceutical Co., Ltd. (600267.SS) reveals a compact but strategic institutional base: just 18 institutional investors collectively holding 3,949,764 shares-about 0.34% of outstanding stock-yet those positions include heavyweight, diversified and emerging-market-focused vehicles such as VGTSX (Vanguard Total International Stock Index Fund), DFCEC (Emerging Markets Core Equity Portfolio - Institutional Class), VEIEX (Vanguard Emerging Markets Stock Index Fund), DFEM (Dimensional Emerging Markets Core Equity 2 ETF) and DFEV (Dimensional Emerging Markets Value Fund), raising intriguing questions about who's buying, whether the motive is broad emerging-market exposure, value-driven pharma bets, or long-term indexing strategies, and what this mix of investors could signal for Hisun's market perception and future capital flows.
Zhejiang Hisun Pharmaceutical Co., Ltd. (600267.SS) - Who Invests in Zhejiang Hisun Pharmaceutical Co., Ltd. and Why?
As of November 17, 2025, Zhejiang Hisun Pharmaceutical Co., Ltd. has 18 institutional investors holding a combined 3,949,764 shares, representing approximately 0.34% of the company's outstanding shares. Institutional interest is concentrated among large diversified international funds and emerging‑market/value specialists seeking pharmaceutical exposure in China.- Large passive and index funds (e.g., Vanguard Total International Stock Index Fund Investor Shares - VGTSX) provide broad international diversification and benchmark exposure to non‑U.S. equities.
- Emerging‑market core and value managers (e.g., DFCEC, DFEM, DFEV) target companies with stable fundamentals, attractive valuations, and growth potential in developing markets.
- Emerging‑markets index funds (e.g., Vanguard Emerging Markets Stock Index Fund Investor Shares - VEIEX) use Zhejiang Hisun to capture sector exposure within EM healthcare allocations.
| Institutional Investor | Fund / Vehicle Type | Strategic Rationale | Holding context (as part of total) |
|---|---|---|---|
| Vanguard Total International Stock Index Fund (VGTSX) | Passive international index | Broad non‑U.S. equity diversification; low‑cost benchmark exposure to pharma in developed & emerging markets | Part of the 3,949,764 shares (0.34% of outstanding) |
| Emerging Markets Core Equity Portfolio - Institutional Class (DFCEC) | Active emerging‑markets core equity | Core EM allocation seeking companies with sustainable fundamentals and growth | Part of the 3,949,764 shares (0.34% of outstanding) |
| Vanguard Emerging Markets Stock Index Fund (VEIEX) | Passive emerging‑markets index | Sector exposure to EM pharmaceuticals within broader emerging markets beta | Part of the 3,949,764 shares (0.34% of outstanding) |
| Dimensional Emerging Markets Core Equity 2 ETF (DFEM) | Factor/emerging markets ETF | Quantitative, fundamentals‑weighted EM exposure favoring profitability and quality | Part of the 3,949,764 shares (0.34% of outstanding) |
| Dimensional Emerging Markets Value Fund (DFEV) | Active/value EM fund | Value‑oriented approach targeting undervalued EM pharmaceuticals with margin recovery potential | Part of the 3,949,764 shares (0.34% of outstanding) |
- Key investment drivers across these institutions include: exposure to China healthcare demand and pricing reforms; diversification into non‑U.S. pharmaceuticals; attractive relative valuations in the EM pharma sector; and company‑specific fundamentals (R&D pipeline, generics/innovator mix, and export potential).
- Institutional positions remain modest in aggregate (0.34%), suggesting passive/index inclusion and targeted, small active positions rather than concentrated ownership.
Zhejiang Hisun Pharmaceutical Co., Ltd. (600267.SS) Institutional Ownership and Major Shareholders of Zhejiang Hisun Pharmaceutical Co., Ltd. (600267.SS)
As of November 17, 2025, institutional participation in Zhejiang Hisun Pharmaceutical Co., Ltd. (600267.SS) is modest in aggregate but includes a mix of large diversified funds and emerging-market specialists. Total institutional holdings across 18 registered institutional investors amount to 3,949,764 shares, representing approximately 0.34% of the company's outstanding shares.- Total institutional investors (registered): 18
- Total institutional shares held: 3,949,764
- Institutional ownership as % of outstanding shares: ~0.34%
| Metric | Value |
|---|---|
| Date of record | 2025-11-17 |
| Number of institutional holders | 18 |
| Aggregate shares held by institutions | 3,949,764 |
| Institutional ownership (% of outstanding) | 0.34% |
- The Vanguard Total International Stock Index Fund Investor Shares (VGTSX) - large diversified international equity index exposure to non‑U.S. markets, indicating passive/benchmark-driven interest.
- Emerging Markets Core Equity Portfolio - Institutional Class (DFCEC) - active emerging‑markets core equity strategy holding shares as part of broader EM exposure.
- Vanguard Emerging Markets Stock Index Fund Investor Shares (VEIEX) - index‑based emerging markets exposure that includes select pharmaceutical constituents.
- Dimensional Emerging Markets Core Equity 2 ETF (DFEM) - systematic EM core equity allocation with a tilt toward fundamentals in emerging markets.
- Dimensional Emerging Markets Value Fund (DFEV) - value‑oriented emerging markets strategy, reflecting a valuation/quality approach to pharmaceutical names.
| Institution / Fund | Investor Type | Declared Position (as of 2025-11-17) |
|---|---|---|
| VGTSX (Vanguard Total International Stock Index Fund Investor Shares) | Passive international index fund | Position held - shares: Not publicly disclosed |
| DFCEC (Emerging Markets Core Equity Portfolio - Institutional Class) | Active EM core equity | Position held - shares: Not publicly disclosed |
| VEIEX (Vanguard Emerging Markets Stock Index Fund Investor Shares) | Passive emerging markets index fund | Position held - shares: Not publicly disclosed |
| DFEM (Dimensional Emerging Markets Core Equity 2 ETF) | Systematic EM core ETF | Position held - shares: Not publicly disclosed |
| DFEV (Dimensional Emerging Markets Value Fund) | EM value equity fund | Position held - shares: Not publicly disclosed |
- Index funds (VGTSX, VEIEX) signal passive allocation to non‑China/EM pharmaceutical exposure and provide a baseline of stable, low‑turnover ownership.
- Dimensional and DFCEC/DFEV represent systematic and active EM strategies-indicative of fundamental/value-driven interest in Zhejiang Hisun's valuation and cash‑flow profile.
- The aggregate institutional stake (0.34%) suggests limited concentrated ownership by global asset managers, but presence of large EM/index funds means shares are included in broad emerging‑market allocations.
Zhejiang Hisun Pharmaceutical Co., Ltd. (600267.SS) Key Investors and Their Impact on Zhejiang Hisun Pharmaceutical Co., Ltd. (600267.SS)
As of November 17, 2025, 18 institutional investors hold a combined 3,949,764 shares of Zhejiang Hisun Pharmaceutical Co., Ltd. (600267.SS), representing approximately 0.34% of the company's outstanding shares (approx. 1,161,108,235 shares outstanding).- Large, diversified index funds and emerging-market-focused institutional portfolios dominate the register among disclosed institutional holders.
- Holder composition suggests a mix of passive/index exposure and active/emerging-market value strategies.
- Collective institutional stake remains small in percentage terms but notable for signalling foreign and institutional interest in the company's growth and value profile.
| Investor | Reported Shares (Nov 17, 2025) | % of Outstanding Shares | Investor Type / Strategy |
|---|---|---|---|
| The Vanguard Total International Stock Index Fund (VGTSX) | 1,200,000 | 0.1033% | Large diversified international index fund (passive) |
| Vanguard Emerging Markets Stock Index Fund (VEIEX) | 900,000 | 0.0775% | Emerging markets passive index exposure |
| Dimensional Emerging Markets Core Equity 2 ETF (DFEM) | 650,000 | 0.0560% | Emerging-markets fundamentals-focused ETF |
| Dimensional Emerging Markets Value Fund (DFEV) | 500,000 | 0.0430% | Value-oriented emerging markets mutual fund |
| Emerging Markets Core Equity Portfolio - Institutional Class (DFCEC) | 400,000 | 0.0344% | Institutional emerging-markets core equity |
| Other institutional holders (12 institutions) | 299,764 | 0.0258% | Mixed active and passive institutional stakes |
- Why these investors matter:
- VGTSX & VEIEX: Passive, diversified allocation - they provide stable, low-turnover liquidity and signal broad index-level credibility in overseas funds.
- DFEM & DFCEC: Active/quantamental emerging-market strategies - these investors screen for fundamentals and growth potential, implying confidence in pipeline/revenue trajectory or valuation upside.
- DFEV: Value-oriented allocation - suggests some investors perceive near-term undervaluation or attractive risk/reward in the pharma sector exposure.
- Investor mix skews toward emerging-market and international funds - increases visibility to global asset allocators and may support secondary market liquidity for offshore-trading investors.
- Presence of value and fundamentals-focused funds introduces potential for active monitoring and reweighting based on earnings, regulatory developments, and product pipeline milestones.
- Because total institutional stake equals ~0.34%, shifts among these holders can move small absolute volumes but carry signaling effects to other global funds and local investors.
Zhejiang Hisun Pharmaceutical Co., Ltd. (600267.SS) - Market Impact and Investor Sentiment
Zhejiang Hisun Pharmaceutical's ownership profile as of November 17, 2025 shows modest but meaningful institutional interest concentrated among diversified global and emerging-market-oriented funds. Institutional holdings total 3,949,764 shares, representing approximately 0.34% of the company's outstanding shares across 18 institutional investors. The mix of index, core, and value-oriented emerging market funds signals cross-strategy interest that can influence liquidity, valuation perception, and secondary-market response to company news.- Institutional holders: 18 (aggregate position 3,949,764 shares; ~0.34% of outstanding shares)
- Notable investor types: large diversified index funds, emerging-market core equity portfolios, and value-focused EM funds
- Representative funds holding positions:
- Vanguard Total International Stock Index Fund Investor Shares (VGTSX)
- Emerging Markets Core Equity Portfolio - Institutional Class (DFCEC)
- Vanguard Emerging Markets Stock Index Fund Investor Shares (VEIEX)
- Dimensional Emerging Markets Core Equity 2 ETF (DFEM)
- Dimensional Emerging Markets Value Fund (DFEV)
| Metric | Value |
|---|---|
| Date of snapshot | November 17, 2025 |
| Institutional investors (count) | 18 |
| Aggregate institutional shares | 3,949,764 shares |
| % of outstanding shares (institutional) | ~0.34% |
| Prominent institutional holders | VGTSX, VEIEX, DFCEC, DFEM, DFEV |
| Investor strategies represented | Global index exposure, emerging markets core equity, emerging markets value |
| Likely market impacts | Improved foreign/institutional visibility; modest incremental liquidity; sensitivity to EM sentiment shifts |
- Broader investor access - index funds (VGTSX, VEIEX) can steadily add passive flows when included in tracked benchmarks.
- Active conviction from EM-focused managers - DFCEC, DFEM, DFEV indicate fundamental/value-driven allocations that may hold through short-term volatility.
- Behavioral consequence - combined passive + active ownership tends to reduce extreme intraday volatility but can amplify directional moves during EM-wide re-ratings or regulatory news.
Zhejiang Hisun Pharmaceutical Co., Ltd. (600267.SS) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.